Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Fetroja for complicated urinary tract infections

Nov. 15, 2019

I-Mab obtains Chinese IND clearance for phase I trials of TJM-2 in rheumatoid arthritis

Nov. 15, 2019

Phase II study of AV-101 in major depressive disorder does not meet primary endpoint

Nov. 15, 2019

Results from SILK cohort evaluating tesevatinib in ADPKD patients presented at Kidney Week

Nov. 15, 2019

New IDO-1 inhibitors identified at Phenex Discovery Verwaltungs

Nov. 15, 2019

Pfizer patents cyclin-dependent kinase inhibitors

Nov. 15, 2019

New mu-opioid receptor agonists identified at Sichuan Kelun-Biotech Biopharmaceutical

Nov. 15, 2019

ViiV Healthcare synthesizes prodrugs of HIV maturation inhibitors

Nov. 15, 2019

Janssen describes compounds for respiratory syncytial virus infections

Nov. 15, 2019

Preclinical data suggest MCLA-129 has potential for NSCLC resistant to EGFR-targeted therapies

Nov. 15, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...